^
BRAF V600E
Thyroid Gland Papillary Carcinoma
trametinib + dabrafenib
Sensitive
:
C1
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Thyroid Gland Papillary Carcinoma
FORE-8394
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
No biomarker
Thyroid Gland Papillary Carcinoma
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Papillary Carcinoma
lenvatinib
Sensitive
:
A1
NTRK2 fusion
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive
:
A2
No biomarker
Thyroid Gland Papillary Carcinoma
denosumab
Sensitive
:
A2
RET fusion
Thyroid Gland Papillary Carcinoma
selpercatinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Papillary Carcinoma
entrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Papillary Carcinoma
entrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Papillary Carcinoma
entrectinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive
:
A2
TMB-H
Thyroid Gland Papillary Carcinoma
pembrolizumab
Sensitive
:
A2
RET fusion
Thyroid Gland Papillary Carcinoma
pralsetinib
Sensitive
:
A2
No biomarker
Thyroid Gland Papillary Carcinoma
cabozantinib tablet
Sensitive
:
A2
BRAF V600E
Thyroid Gland Papillary Carcinoma
vemurafenib
Sensitive
:
C1
BRAF V600
Thyroid Gland Papillary Carcinoma
vemurafenib + cobimetinib
Sensitive
:
C1
BRAF V600E
Thyroid Gland Papillary Carcinoma
vemurafenib + cobimetinib
Sensitive
:
C1
BRAF mutation
Thyroid Gland Papillary Carcinoma
vemurafenib
Sensitive
:
C2
BRAF mutation
Thyroid Gland Papillary Carcinoma
FORE-8394 + cobicistat
Sensitive
:
C3
BRAF V600
Thyroid Gland Papillary Carcinoma
BGB-283
Sensitive
:
C3
BRAF mutation
Thyroid Gland Papillary Carcinoma
dabrafenib
Sensitive
:
C3
RET fusion
Thyroid Gland Papillary Carcinoma
cabozantinib tablet
Sensitive
:
C3
BRAF mutation
Thyroid Gland Papillary Carcinoma
trametinib + dabrafenib
Sensitive
:
C3
BRAF V600E
Thyroid Gland Papillary Carcinoma
siltuximab
Sensitive
:
C4
PDGFRB overexpression
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive
:
C4
EGFR overexpression
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive
:
C4
BRAF V600
Thyroid Gland Papillary Carcinoma
dabrafenib + SNR1611
Sensitive
:
C4
NCOA4-RET fusion
Thyroid Gland Papillary Carcinoma
lenvatinib
Sensitive
:
C4
TPM3-NTRK1 fusion
Thyroid Gland Papillary Carcinoma
AB-106
Sensitive
:
C4
GLI3 overexpression
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive
:
C4
GLI2 overexpression
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive
:
C4
GLI1 overexpression
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive
:
C4
TPM3-NTRK1 fusion
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive
:
C4